BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates
Sukhtankar, Devki D.
Czoty, Paul W.
DeLoid, Heather B.
Husbands, Stephen M.
AffiliationWake Forest University
Wakayama Medical University
University of Bath
Wake Forest Baptist Medical Center
Florida Atlantic University
W.G. Hefner Veterans Affairs Medical Center
Subject Categories::B200 Pharmacology, Toxicology and Pharmacy
MetadataShow full item record
AbstractBackground: The marked increase in mis-use of prescription opioids has greatly affected our society. One potential solution is to develop improved analgesics which have agonist action at both mu opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptors. BU10038 is a recently identified bifunctional MOP/NOP partial agonist. The aim of this study was to determine the functional profile of systemic or spinal delivery of BU10038 in primates after acute and chronic administration. Methods: A series of behavioural and physiological assays have been established specifically to reflect the therapeutic (analgesia) and side-effects (abuse potential, respiratory depression, itch, physical dependence, and tolerance) of opioid analgesics in rhesus monkeys. Results: After systemic administration, BU10038 (0.001–0.01 mg kg−1) dose-dependently produced long-lasting antinociceptive and antihypersensitive effects. Unlike the MOP agonist oxycodone, BU10038 lacked reinforcing effects (i.e. little or no abuse liability), and BU10038 did not compromise the physiological functions of primates including respiration, cardiovascular activities, and body temperature at antinociceptive doses and a 10–30-fold higher dose (0.01–0.1 mg kg−1). After intrathecal administration, BU10038 (3 μg) exerted morphine-comparable antinociception and antihypersensitivity without itch scratching responses. Unlike morphine, BU10038 did not cause the development of physical dependence and tolerance after repeated and chronic administration. Conclusions: These in vivo findings demonstrate the translational potential of bifunctional MOP/NOP receptor agonists such as BU10038 as a safe, non-addictive analgesic with fewer side-effects in primates. This study strongly supports that bifunctional MOP/NOP agonists may provide improved analgesics and an alternative solution for the ongoing prescription opioid crisis.
CitationKiguchi N, Ding H, Cami-Kobeci G, Sukhtankar DD, Czoty PW, DeLoid HB, Hsu FC, Toll L, Husbands SM, Ko MC (2019) 'BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates', British Journal of Anaesthesia, 122 (6), pp.e146-e156.
JournalBritish Journal of Anaesthesia
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Green - can archive pre-print and post-print or publisher's version/PDF
- A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
- Authors: Ding H, Kiguchi N, Yasuda D, Daga PR, Polgar WE, Lu JJ, Czoty PW, Kishioka S, Zaveri NT, Ko MC
- Issue date: 2018 Aug 29
- Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
- Authors: Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC
- Issue date: 2013 Jul
- A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates.
- Authors: Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, Husbands SM, Ko MC
- Issue date: 2016 Sep 13
- [Therapeutic potentials of safe opioid analgesics targeting nociceptin/orphanin FQ peptide receptor].
- Authors: Kiguchi N, Kishioka S, Ko MC
- Issue date: 2021
- Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.
- Authors: Kiguchi N, Ding H, Kishioka S, Ko MC
- Issue date: 2020